| Author (Corporate) | European Medicines Agency |
|---|---|
| Series Title | Press Release |
| Series Details | EMA/CHMP/483851/2011 (23.6.11) |
| Publication Date | 23/06/2011 |
| Content Type | News |
|
The European Medicines Agency (EMA), is currently reviewing results from various studies and reports on pioglitazone-containing medicines and the occurrence of bladder cancer, to assess their impact on the balance of benefits and risks of these medicines. The Committee for Medicinal Products for Human Use (CHMP) will finalise its review in July 2011 and make recommendations on the future use of these medicines. |
|
| Source Link | http://www.ema.europa.eu/ema/index.jsp?curl=pages/news_and_events/news/2011/06/news_detail_001284.jsp&murl=menus/news_and_events/news_and_events.jsp&mid=WC0b01ac058004d5c1 |
| Related Links |
|
| Subject Categories | Health |
| Countries / Regions | Europe, France |
